Publications by authors named "Franz Woltering"

Claim this Profile
R
Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensions.
Vera Bril, Artur Drużdż, Julian Grosskreutz, Ali A Habib, Renato Mantegazza, Franz Woltering

J Neuromuscul Dis· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety of cyclical rozanolixizumab in patients with generalized myasthenia gravis: Results from the Phase 3 MycarinG study and an open-label extension.
Ali A Habib, Artur Drużdż, Julian Grosskreutz, Renato Mantegazza, Sabrina Sacconi, Franz Woltering

J Neuromuscul Dis· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of chronic weekly rozanolixizumab in generalized myasthenia gravis: the randomized open-label extension MG0004 study.
Vera Bril, Artur Drużdż, Julian Grosskreutz, Ali A Habib, Henry J Kaminski, Franz Woltering

J Neurol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase III MycarinG study.
Ali A Habib, Sabrina Sacconi, Giovanni Antonini, Elena Cortés-Vicente, Julian Grosskreutz, Franz Woltering

Ther Adv Neurol Disord· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
Vera Bril, Artur Drużdż, Julian Grosskreutz, Ali A Habib, Renato Mantegazza, Franz Woltering

Lancet Neurol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Rozanolixizumab in Moderate to Severe Generalized Myasthenia Gravis: A Phase 2 Randomized Control Trial.
Vera Bril, Michael Benatar, Henning Andersen, John Vissing, Melissa Brock, Franz Woltering

Neurology· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia.
Tadeusz Robak, Maciej Kaźmierczak, Isidro Jarque, Vasile Musteata, Jacek Treliński, Franz Woltering

Blood Adv· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of using a wearable device on clinical decision-making and motor symptoms in patients with Parkinson's disease starting transdermal rotigotine patch: A pilot study.
Stuart H Isaacson, Babak Boroojerdi, Olga Waln, Martha McGraw, David L Kreitzman, Franz Woltering

Parkinsonism Relat Disord· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage.
Nir Giladi, Anthony P Nicholas, Mahnaz Asgharnejad, Elisabeth Dohin, Franz Woltering

J Parkinsons Dis· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of 6-month earlier versus postponed initiation of rotigotine on long-term outcome: post hoc analysis of patients with early Parkinson's disease with mild symptom severity.
Lars Timmermann, Mahnaz Asgharnejad, Babak Boroojerdi, Elisabeth Dohin, Franz Woltering

Expert Opin Pharmacother· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis